NCT05813795CompletedPhase 3
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
A Phase 3, Multi-center, Randomized, Double-Blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Adults With Overweight or Obesity (SLIMMER)
Source: ClinicalTrials.gov · Last updated 30 Apr 2025
Brief summary (registry, in English)
The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 664 (actual)
- First submitted
- 20 Mar 2023
- Start date
- 5 Apr 2023
- Primary completion date
- 20 Jun 2024
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Diseases
- Obesity
- NCT number
- NCT05813795
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 664
- From 5 Apr 2023 to the primary completion date, 20 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Within 3 months before screening, history of using the following drugs or treatments:
- Any approved or unapproved weight-loss drugs or Chinese herbs or health products that affect body weight.
- Any hypoglycemic medication.
- Any medication that may cause significant weight gain, including systemic glucocorticoid treatment, tricyclic anti-depressants, anti-epileptic and antipsychotics.
- Any investigational drug, vaccine, or medical device.
Other illness
- Obesity induced by endocrine diseases such as hypothyroidism, Cushing Syndrome, etc.
- History of bariatric surgery (except liposuction \>1 year ago) or planned bariatric surgery during the study period.
Who the study is looking for
- Male or female, 18-75 years old, inclusive;
- BMI between 24.0 to 28.0 kg/m2 with at least one comorbidity, including prediabetes, hypertension, hyperlipidemia, fatty liver , obstructive sleep apnea syndrome, etc.; or BMI ≥ 28 kg/m2 with or without comorbidities.
- Weight change of no more than 5% (based on self-report), with diet and exercise alone, within 3 months before screening.
- Willing and able to maintain stable diet and exercise during the study period.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.